Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists hunt for sepsis clues in blood genes

NCT ID NCT07320638

Knowledge-focused Sponsor: Ruijin Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at a gene called TRIM25 in blood cells of people with sepsis—a life-threatening infection that can damage organs. Researchers will compare these gene activity levels between sepsis patients and non-sepsis patients. The goal is to find new markers that could lead to better ways to diagnose and treat sepsis.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 65 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2021

Expected to finish

Jul 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population will consist of two primary, non-overlapping groups of adult participants recruited from the hospital setting: Sepsis Patient Cohort (Case Group): Adult patients (aged 18 years or older) who are diagnosed with Sepsis based on the Sepsis-3 clinical criteria (or the most current widely accepted clinical definitions) upon admission to the Intensive Care Unit (ICU) or general ward. Non-Sepsis Control Cohort (Control Group): Adult patients (aged 18 years or older) who are admitted to the hospital with non-infectious conditions or healthy volunteers, provided they do not meet the criteria for sepsis or severe infection at the time of enrollment. The enrollment process for both groups will be observational, involving the collection of a single peripheral blood sample for the isolation of peripheral blood mononuclear cells (PBMCs) and serum, as well as collection of relevant clinical data.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 1\. SOFA score \>=2; 2. Aged 18-70 years male and female; 3. Hospitalization. Exclusion Criteria: * 1\. Immune system disease, such as HIV; 2. Disease that possibly affect the function of immune system, such as tumor and chronic viral infection; 3. Patients that treated with massive cortical hormone (\>200mg/d) or immunosuppressant; 4. Pregnant or lactation women.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Sepsis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

infectious disease with sepsis Sepsis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Sepsis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Shanghai JiaoTong University School of Medicine

    Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.